Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Silver sulfadiazine + chlorhexidine gluconate is a topical combination drug used primarily for the prevention and treatment of infections in burn wounds and other skin injuries. Silver sulfadiazine is a sulfonamide antibiotic that releases silver ions, which disrupt bacterial cell walls and inhibit folic acid synthesis required for bacterial growth. Chlorhexidine gluconate is an antiseptic that disrupts microbial cell membranes, providing broad-spectrum antimicrobial activity. Together, they offer synergistic action against a wide range of gram-positive and gram-negative bacteria—including resistant strains—making this combination especially effective in reducing wound sepsis risk in burn patients. The product is typically formulated as a cream or ointment for external use only[1][2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on silver sulfadiazine + chlorhexidine gluconate.